-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Galapagos (NASDAQ:GLPG) Shares Gap Up to $48.16
Galapagos (NASDAQ:GLPG) Shares Gap Up to $48.16
Galapagos NV (NASDAQ:GLPG – Get Rating) shares gapped up prior to trading on Monday . The stock had previously closed at $48.16, but opened at $50.65. Galapagos shares last traded at $51.65, with a volume of 1,778 shares trading hands.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the stock. Jefferies Financial Group cut shares of Galapagos from a "hold" rating to an "underperform" rating in a research report on Monday, July 25th. Morgan Stanley cut shares of Galapagos from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $80.00 to $61.00 in a report on Friday, September 9th. Finally, Royal Bank of Canada decreased their price objective on shares of Galapagos from $62.00 to $55.00 in a report on Monday, August 8th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $62.75.
Get Galapagos alerts:Galapagos Stock Down 5.4 %
The stock's 50 day simple moving average is $52.54 and its two-hundred day simple moving average is $57.40.
Galapagos (NASDAQ:GLPG – Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.79) by $0.48. Galapagos had a negative net margin of 16.90% and a negative return on equity of 3.02%. The firm had revenue of $146.62 million for the quarter, compared to analyst estimates of $95.44 million. On average, equities research analysts expect that Galapagos NV will post -3.23 EPS for the current year.Institutional Trading of Galapagos
A number of institutional investors have recently made changes to their positions in the business. International Biotechnology Trust PLC bought a new stake in shares of Galapagos in the second quarter worth $123,000. Driehaus Capital Management LLC lifted its position in shares of Galapagos by 6.9% in the second quarter. Driehaus Capital Management LLC now owns 510,649 shares of the biotechnology company's stock worth $28,494,000 after purchasing an additional 33,034 shares in the last quarter. Quantbot Technologies LP lifted its position in shares of Galapagos by 100.0% in the second quarter. Quantbot Technologies LP now owns 1,400 shares of the biotechnology company's stock worth $78,000 after purchasing an additional 700 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Galapagos by 193.8% in the second quarter. Renaissance Technologies LLC now owns 248,300 shares of the biotechnology company's stock worth $13,855,000 after purchasing an additional 163,800 shares in the last quarter. Finally, Hudson Bay Capital Management LP lifted its position in shares of Galapagos by 566.2% in the second quarter. Hudson Bay Capital Management LP now owns 216,500 shares of the biotechnology company's stock worth $12,081,000 after purchasing an additional 184,000 shares in the last quarter. Institutional investors own 19.48% of the company's stock.
About Galapagos
(Get Rating)
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis.
Featured Stories
- Get a free copy of the StockNews.com research report on Galapagos (GLPG)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.
Galapagos NV (NASDAQ:GLPG – Get Rating) shares gapped up prior to trading on Monday . The stock had previously closed at $48.16, but opened at $50.65. Galapagos shares last traded at $51.65, with a volume of 1,778 shares trading hands.
加拉帕戈斯公司(纳斯达克代码:Glpg-Get Rating)的股票在周一交易前大幅上涨。该股此前收盘报48.16美元,开盘报50.65美元。加拉帕戈斯的股票最新报51.65美元,成交量为1,778股。
Analysts Set New Price Targets
分析师设定新的价格目标
Several equities research analysts have recently commented on the stock. Jefferies Financial Group cut shares of Galapagos from a "hold" rating to an "underperform" rating in a research report on Monday, July 25th. Morgan Stanley cut shares of Galapagos from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $80.00 to $61.00 in a report on Friday, September 9th. Finally, Royal Bank of Canada decreased their price objective on shares of Galapagos from $62.00 to $55.00 in a report on Monday, August 8th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $62.75.
几位股票研究分析师最近对该股发表了评论。7月25日,杰富瑞金融集团在一份研究报告中将加拉帕戈斯的股票评级从持有下调至表现不佳。在9月9日星期五的一份报告中,摩根士丹利将加拉帕戈斯股票的评级从增持下调至持平,并将该公司的目标价从80美元下调至61美元。最后,加拿大皇家银行在8月8日星期一的一份报告中将加拉帕戈斯股票的目标价从62.00美元下调至55.00美元。一名分析师对该股的评级为卖出,五名分析师给出了持有评级,两名分析师给出了该公司股票的买入评级。根据MarketBeat的数据,该公司目前的平均评级为持有,共识目标价为62.75美元。
Galapagos Stock Down 5.4 %
加拉帕戈斯股市下跌5.4%
The stock's 50 day simple moving average is $52.54 and its two-hundred day simple moving average is $57.40.
该股的50日简单移动均线切入位为52.54美元,200日简单移动均线切入位为57.40美元。
Institutional Trading of Galapagos
加拉帕戈斯的机构交易
A number of institutional investors have recently made changes to their positions in the business. International Biotechnology Trust PLC bought a new stake in shares of Galapagos in the second quarter worth $123,000. Driehaus Capital Management LLC lifted its position in shares of Galapagos by 6.9% in the second quarter. Driehaus Capital Management LLC now owns 510,649 shares of the biotechnology company's stock worth $28,494,000 after purchasing an additional 33,034 shares in the last quarter. Quantbot Technologies LP lifted its position in shares of Galapagos by 100.0% in the second quarter. Quantbot Technologies LP now owns 1,400 shares of the biotechnology company's stock worth $78,000 after purchasing an additional 700 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Galapagos by 193.8% in the second quarter. Renaissance Technologies LLC now owns 248,300 shares of the biotechnology company's stock worth $13,855,000 after purchasing an additional 163,800 shares in the last quarter. Finally, Hudson Bay Capital Management LP lifted its position in shares of Galapagos by 566.2% in the second quarter. Hudson Bay Capital Management LP now owns 216,500 shares of the biotechnology company's stock worth $12,081,000 after purchasing an additional 184,000 shares in the last quarter. Institutional investors own 19.48% of the company's stock.
一些机构投资者最近改变了他们在该业务中的头寸。国际生物技术信托公司在第二季度购买了加拉帕戈斯价值12.3万美元的新股。Driehaus Capital Management LLC在第二季度将其在加拉帕戈斯股票的头寸提高了6.9%。Driehaus Capital Management LLC现在拥有510,649股这家生物技术公司的股票,价值28,494,000美元,上个季度又购买了33,034股。Quantbot Technologies LP在第二季度将其在加拉帕戈斯股票的头寸提高了100.0%。Quantbot Technologies LP现在持有这家生物技术公司1,400股股票,价值7.8万美元,上个季度又购买了700股。复兴科技有限责任公司在第二季度将其在加拉帕戈斯股票的头寸提高了193.8%。复兴科技有限公司现在持有这家生物技术公司248,300股股票,价值13,855,000美元,上个季度又购买了163,800股。最后,哈德逊湾资本管理有限公司在第二季度将其在加拉帕戈斯股票的头寸提高了566.2%。Hudson Bay Capital Management LP在上个季度又购买了184,000股后,现在拥有216,500股这家生物技术公司的股票,价值12,081,000美元。机构投资者持有该公司19.48%的股份。
About Galapagos
关于加拉帕戈斯
(Get Rating)
(获取评级)
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis.
加拉帕戈斯公司是一家综合性生物制药公司,从事各种药物的发现、开发和商业化,以满足高度未得到满足的医疗需求。其流水线产品包括非戈替尼,一种JAK1抑制剂,正处于临床试验的不同阶段,用于治疗类风湿性关节炎、克罗恩病、溃疡性结肠炎、小肠CD、瘘管性CD、强直性脊柱炎、牛皮癣关节炎和葡萄膜炎。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Galapagos (GLPG)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 免费获取StockNews.com关于加拉帕戈斯的研究报告(GLPG)
- 这三份报告将告诉我们许多关于当前经济的情况。
- 下面的五个是不是打得太高了?
- 这就是现在对标准普尔500指数的预期
- 关于甲骨文的FQ1报告,你需要知道的两件事
- 波动市场的三只价值股
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.
接受加拉帕戈斯日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对加拉帕戈斯和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧